Investor Relations

Upcoming Events

2022 Annual General Meeting of Shareholders

19th Annual Craig-Hallum Institutional Investor Conference

BTIG Biotechnology Conference 2022

Most Recent Business Quarterly Update

View Q1 2022 Update

Company Overview

DiaMedica Therapeutics Inc. (Nasdaq: DMAC) is a clinical stage biopharmaceutical company developing recombinant proteins to improve the lives of patients who experience a stroke or recurrent strokes and kidney diseases.

Investor Contact Information

Company

DiaMedica Therapeutics, Inc.
Two Carlson Parkway,
Suite 260
Minneapolis, MN 55447

Investor Relations

DiaMedica Therapeutics Inc.
Scott Kellen
Chief Financial Officer
T: (763) 496-5192
F: (763) 710-4456
skellen@diamedica.com